VistaGen Therapeutics Accounts Receivable

VistaGen Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

VistaGen Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

VistaGen Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), VistaGen Therapeutics's accounts receivable are only considered to be worth 75% of book value:

VistaGen Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

VistaGen Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

VistaGen Therapeutics Business Description

Industry

Healthcare » Biotechnology NAICS : 325412 SIC : 2834

Comparable Companies

NAS:ALT NAS:MGNX NAS:TRDA NAS:KALV NAS:JNCE NAS:STRO AMEX:LCTX NAS:XOMA NAS:GTHX NAS:NVCT OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Executives

Saxe Jon S	director	FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane	officer: VP, CFO AND SECRETARY	5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph	director, officer: PRES./CHIEF SCIENTIFIC OFFICER	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan	officer: CHIEF MEDICAL OFFICER	343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A.	officer: VP CORPORATE DEVELOPMENT	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B	director	343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J.	director	C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle	director	255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin	officer: VP CORPORATE DEVELOPMENT	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A.	director	384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie	director, 10 percent owner, officer: PRESIDENT	13834 W. HOYT ROAD RATHDRUM ID 83858